Promising Future for Tarsus Pharmaceuticals: Strong Q3 Results and Strategic Wins Boost Buy Rating

Jason Gerberry, an analyst from Bank of America Securities, reiterated the Buy rating on Tarsus Pharmaceuticals (TARS – Research Report). The associated price target is $68.00.

Jason Gerberry has given his Buy rating due to a combination of factors that highlight the promising future of Tarsus Pharmaceuticals. The company reported stronger-than-expected third-quarter results, with revenues surpassing forecasts and a positive outlook for the fourth quarter. This performance, coupled with successful Medicare Part D contracting wins, has led to an accelerated projection of peak sales and increased revenue forecasts for the years 2025 to 2028.
Furthermore, the demand for Tarsus’s product, Xdemvy, is expected to rise significantly in the fourth quarter, driven by increased healthcare provider utilization, sales force expansion, and strategic timing before year-end deductible resets. The company has also secured broad payer coverage at favorable pricing, covering 80% of insured patients, which should alleviate investor concerns about reimbursement issues. Overall, the strong market position and growth potential of Xdemvy, along with favorable financial projections, support Gerberry’s optimistic valuation and Buy rating.

In another report released today, Barclays also maintained a Buy rating on the stock with a $60.00 price target.

TARS’s price has also changed moderately for the past six months – from $38.370 to $46.505, which is a 21.20% increase.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Tarsus Pharmaceuticals (TARS) Company Description:

Tarsus Pharmaceuticals Inc is a late clinical-stage biopharmaceutical company. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company’s lead candidate TP-03, is a novel drug that targets the Demodex mite nervous system to kill the mites.